Replies to post #13593 on Ariad Pharmaceuticals Inc fka ARIA

[biggene]

"Second-generation ALK inhibitors such as AP-26113 and X-276 are considered more potent and selective inhibitors of ALK than crizotinib. AP-26113, an orally bioavailable inhibitor of ALK with undisclosed structure, is developed by Ariad [63]. During preclinical investigation, AP-26113 has been shown to inhibit not only the wild-type ALK but also mutant forms of ALK, which are resistant to the first-generation ALK inhibitor such as crizotinib. Further studies have demonstrated AP-26113 is at least 10-fold more potent and selective in ALK inhibition than crizotinib [64,65]."

[biomaven0]

Seems like an out-of-date article for one that was just published. Completely misses the Novartis ALK drug LDK378 that's been in Phase I since the beginning of the year:

http://www.clinicaltrials.gov/ct2/show/study/NCT01283516?term=alk&rank=1&show_locs=Y#locn

On '113, just re-hashes some of the earlier information that was disclosed a while back.

Peter